Dr. Alter Discusses the Immunotherapy Provenge

Video

Dr. Robert Alter from John Theurer Cancer Center Discusses the Immunotherapy Provenge

Robert S. Alter, MD, co-chief, Urologic Oncology, John Theurer Cancer Center, describes the immunotherapy Provenge (sipuleucel-T) as a state-of-the-art breakthrough in the way prostate cancer patients are treated.

Vaccine therapies, such as Provenge, utilize the patient's immune system to fight tumor cells. In comparison to standard chemotherapy and newer targeted therapies Provenge has fewer toxicities and is better tolerated. The drug is a very short coursed therapy that does not subject patients to taking medications on a daily basis, which prevents many of the common toxicities that accompany daily doses of chemotherapy.

Alter describes Provenge as a durable therapy that effectively improves quality-of-life for patients.

Related Videos
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD